Suppr超能文献

神经母细胞瘤中的端粒生物学:端粒结合蛋白和端粒的替代强化。

Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.

机构信息

Department of Surgery, Graduate School of Biomedical Science, Hiroshima University, Hiroshima 734-8551, Japan.

出版信息

J Pediatr Surg. 2009 Dec;44(12):2258-66. doi: 10.1016/j.jpedsurg.2009.07.046.

Abstract

PURPOSE

Neuroblastoma (NBL) shows remarkable biologic heterogeneity, resulting in favorable or unfavorable prognoses. Previously, we reported that most unfavorable NBLs express high telomerase activity to maintain telomere length. Recently, telomere binding proteins (TBPs) and alternative lengthening of telomeres (ALTs) have been identified as key factors of telomere maintenance.

METHODS

To evaluate the correlation between telomerase activity, telomere length, and the expression levels of TBPs in NBL, we analyzed and quantified these factors in 121 untreated NBLs.

RESULTS

Shortened and elongated telomeres were detected in 21 (17.3%) and 11 cases (9.0%), respectively, and there was a significant correlation between telomere length and the length of the 3'-overhang. The tumors with shortened or elongated telomeres showed significant lower expression of TBPs, except for RAP1. Although telomerase activity did not correlate with telomere length, 16 of 22 cases with high telomerase activity and 5 of 9 cases (ALT tumors) that showed long telomeres without high telomerase activity resulted in death. High-dose chemotherapy did not have much effect on these deceased ALT cases, but their survival periods were more than 2 years and relatively long compared with the deceased cases with nonelongated telomeres, suggesting that chemoresistance in ALT tumors may be related to slow growth rates.

CONCLUSIONS

High telomerase activity is a poor prognostic factor in NBL. In the cases without high telomerase activity, those with elongated telomere also showed poor outcomes because of chemoresistance. Therefore, ALT and TBPs may be biomarkers for chemosensitivity in NBL. Thus, a better understanding of telomere biology may help define the characteristics of individual NBLs.

摘要

目的

神经母细胞瘤(NBL)表现出显著的生物学异质性,导致预后良好或不良。此前,我们报道大多数不良预后的 NBL 表达高端粒酶活性以维持端粒长度。最近,端粒结合蛋白(TBPs)和端粒的替代性延长(ALT)已被确定为端粒维持的关键因素。

方法

为了评估端粒酶活性、端粒长度与 NBL 中 TBPs 表达水平之间的相关性,我们分析和定量了 121 例未经治疗的 NBL 中的这些因素。

结果

分别检测到 21 例(17.3%)和 11 例(9.0%)的短缩和延长的端粒,端粒长度与 3'-突出端的长度之间存在显著相关性。具有短缩或延长端粒的肿瘤 TBPs 表达显著降低,除了 RAP1。虽然端粒酶活性与端粒长度没有相关性,但在 22 例高端粒酶活性病例中有 16 例和在 9 例(ALT 肿瘤)中没有高端粒酶活性但显示长端粒的病例中,导致死亡。高剂量化疗对这些 ALT 死亡病例没有太大影响,但它们的生存时间超过 2 年,与没有端粒延长的死亡病例相比相对较长,表明 ALT 肿瘤中的化疗耐药性可能与生长速度较慢有关。

结论

高端粒酶活性是 NBL 的不良预后因素。在没有高端粒酶活性的病例中,由于化疗耐药性,那些端粒延长的病例也表现出不良结局。因此,ALT 和 TBPs 可能是 NBL 化疗敏感性的生物标志物。因此,更好地了解端粒生物学可能有助于确定个体 NBL 的特征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验